H.C. Wainwright analyst Emily Bodnar downgraded IO Biotech (IOBT) to Neutral from Buy with no price target
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IOBT:
- FDA Recommends Against IO Biotech’s Cylembio Application
- IO Biotech says FDA reccomends not submitting BLA based on IOB-013 trial data
- IO Biotech implements plan to conserve capital, 50% reduction in full-time staff
- IO Biotech Reports Q2 2025 Financial Results
- IO Biotech’s Cylembio Shows Promise Despite Missed Endpoint, Buy Rating Affirmed